aztreonam has been researched along with Meningitis in 18 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Meningitis: Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "10 patients with meningitis due to unusual gram-negative organisms (Pseudomonas, Proteus, Salmonella and Klebsiella) were effectively treated with aztreonam." | 7.68 | Aztreonam for treating meningitis caused by gram-negative rods. ( Bishay, E; Farid, Z; Girgis, N; Kilpatrick, M, 1991) |
| "The monobactam aztreonam was used to treat 22 young patients with meningitis caused by gram-negative bacilli." | 7.67 | Aztreonam in the treatment of bacterial meningitis. ( Ayroza-Galvão, PA; Barbosa Júnior, SP; Cavalcante, NJ; Lorenco, R; Maassen, S; Martino, MD; Milstein-Kuschnaroff, TM; Mimica, IM; Mimica, LM, 1989) |
| "This study examined the penetration of aztreonam into the cerebrospinal fluid (CSF) and brain in noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa." | 7.67 | Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa. ( Bodem, CR; Laun, PR; Strausbaugh, LJ, 1986) |
| "A monotherapy of aztreonam (AZT) was applied to 9 male and 3 female pediatric patients of ages ranging from 2 months to 8 years and 11 months with serious purulent meningitis." | 7.67 | [Clinical evaluation of aztreonam against pediatric purulent meningitis]. ( Fujii, R; Furukawa, S; Haruta, T; Kitamura, I; Kobayashi, Y; Meguro, H; Nishimura, T; Ogura, H; Okada, T; Toyonaga, Y, 1988) |
| "The penetration of aztreonam into the cerebrospinal fluid was determined in 16 patients with bacterial meningitis undergoing treatment with other antibiotics." | 7.67 | Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis. ( Decazes, JM; Meulemans, A; Modai, J; Vittecoq, D; Wolff, M, 1986) |
| "The penetration of aztreonam into cerebrospinal fluid was 7 to 15% and 9 to 25%, respectively, in experimental Haemophilus influenzae type b and Escherichia coli K1 meningitis." | 7.67 | Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1. ( McCracken, GH; Olsen, KD; Sakata, Y, 1985) |
| "Aztreonam (SQ 26,776), a new monocyclic beta-lactam agent, was compared with ampicillin, ampicillin plus chloramphenicol, and gentamicin in rabbits with experimental meningitis induced by, respectively, ampicillin-susceptible Haemophilus influenzae, ampicillin-resistant H." | 7.66 | Evaluation of aztreonam in experimental bacterial meningitis and cerebritis. ( Brodeur, JP; Foresman, P; Gratz, JC; Rodeheaver, G; Scheld, WM, 1983) |
| "10 patients with meningitis due to unusual gram-negative organisms (Pseudomonas, Proteus, Salmonella and Klebsiella) were effectively treated with aztreonam." | 3.68 | Aztreonam for treating meningitis caused by gram-negative rods. ( Bishay, E; Farid, Z; Girgis, N; Kilpatrick, M, 1991) |
| "Aztreonam was administered to 20 children diagnosed as having any of the following infections: urinary tract infection, pneumonia, meningitis, and abscess of the appendix." | 3.67 | Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. ( Arango, A; Benítez, G; Castrillón, AL; Harry, N; Mejía, GI; Restrepo, F; Trujillo, H, 1989) |
| "The monobactam aztreonam was used to treat 22 young patients with meningitis caused by gram-negative bacilli." | 3.67 | Aztreonam in the treatment of bacterial meningitis. ( Ayroza-Galvão, PA; Barbosa Júnior, SP; Cavalcante, NJ; Lorenco, R; Maassen, S; Martino, MD; Milstein-Kuschnaroff, TM; Mimica, IM; Mimica, LM, 1989) |
| "This study examined the penetration of aztreonam into the cerebrospinal fluid (CSF) and brain in noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa." | 3.67 | Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa. ( Bodem, CR; Laun, PR; Strausbaugh, LJ, 1986) |
| "A monotherapy of aztreonam (AZT) was applied to 9 male and 3 female pediatric patients of ages ranging from 2 months to 8 years and 11 months with serious purulent meningitis." | 3.67 | [Clinical evaluation of aztreonam against pediatric purulent meningitis]. ( Fujii, R; Furukawa, S; Haruta, T; Kitamura, I; Kobayashi, Y; Meguro, H; Nishimura, T; Ogura, H; Okada, T; Toyonaga, Y, 1988) |
| "The penetration of aztreonam into the cerebrospinal fluid was determined in 16 patients with bacterial meningitis undergoing treatment with other antibiotics." | 3.67 | Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis. ( Decazes, JM; Meulemans, A; Modai, J; Vittecoq, D; Wolff, M, 1986) |
| "The penetration of aztreonam into cerebrospinal fluid was 7 to 15% and 9 to 25%, respectively, in experimental Haemophilus influenzae type b and Escherichia coli K1 meningitis." | 3.67 | Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1. ( McCracken, GH; Olsen, KD; Sakata, Y, 1985) |
| "The penetration of aztreonam (AZT), a new synthetic monobactam, into cerebrospinal fluid (CSF) and the clinical studies for bacterial infections were carried out." | 3.67 | [Clinical evaluation on aztreonam in pediatric field and fundamental study on its penetration into cerebrospinal fluid]. ( Furukawa, S; Okada, T, 1985) |
| "Aztreonam (SQ 26,776), a new monocyclic beta-lactam agent, was compared with ampicillin, ampicillin plus chloramphenicol, and gentamicin in rabbits with experimental meningitis induced by, respectively, ampicillin-susceptible Haemophilus influenzae, ampicillin-resistant H." | 3.66 | Evaluation of aztreonam in experimental bacterial meningitis and cerebritis. ( Brodeur, JP; Foresman, P; Gratz, JC; Rodeheaver, G; Scheld, WM, 1983) |
| "Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections." | 1.28 | Successful response of severe neonatal gram-negative infection to treatment with aztreonam. ( Constantopoulos, A; Loupa, H; Papoulias, G; Thomaidou, L, 1989) |
| "Aztreonam was administered as a single, 2-g intravenous dose to 25 patients with noninflamed meninges and to 9 patients with inflamed meninges." | 1.27 | Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges. ( Baggett, JW; Berry, AJ; Duma, RJ; Platt, TB; Smith, SM; Swabb, EA, 1984) |
| "Aztreonam is a monocyclic beta-lactam antibiotic that inhibits aerobic gram-negative bacilli, including beta-lactamase-producing species." | 1.27 | Current state of infectious diseases--potential areas of directed therapy with aztreonam. ( Neu, HC, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (88.89) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scheld, WM | 1 |
| Brodeur, JP | 1 |
| Gratz, JC | 1 |
| Foresman, P | 1 |
| Rodeheaver, G | 1 |
| Duma, RJ | 1 |
| Berry, AJ | 1 |
| Smith, SM | 1 |
| Baggett, JW | 1 |
| Swabb, EA | 1 |
| Platt, TB | 2 |
| Bosso, JA | 1 |
| Black, PG | 1 |
| Kilpatrick, M | 1 |
| Girgis, N | 1 |
| Farid, Z | 1 |
| Bishay, E | 1 |
| Constantopoulos, A | 1 |
| Thomaidou, L | 1 |
| Loupa, H | 1 |
| Papoulias, G | 1 |
| Feris, J | 1 |
| Moledina, N | 1 |
| Rodriguez, WJ | 1 |
| Khan, WN | 1 |
| Puig, J | 1 |
| Wiedermann, BL | 1 |
| Ahmad, S | 1 |
| Trujillo, H | 1 |
| Harry, N | 1 |
| Arango, A | 1 |
| Benítez, G | 1 |
| Restrepo, F | 1 |
| Mejía, GI | 1 |
| Castrillón, AL | 1 |
| Ayroza-Galvão, PA | 1 |
| Milstein-Kuschnaroff, TM | 1 |
| Mimica, IM | 1 |
| Maassen, S | 1 |
| Barbosa Júnior, SP | 1 |
| Cavalcante, NJ | 1 |
| Lorenco, R | 1 |
| Mimica, LM | 1 |
| Martino, MD | 1 |
| Strausbaugh, LJ | 1 |
| Bodem, CR | 1 |
| Laun, PR | 1 |
| Fujii, R | 1 |
| Meguro, H | 1 |
| Nishimura, T | 1 |
| Kobayashi, Y | 2 |
| Haruta, T | 2 |
| Toyonaga, Y | 1 |
| Okada, T | 2 |
| Furukawa, S | 2 |
| Kitamura, I | 1 |
| Ogura, H | 1 |
| Lebel, MH | 1 |
| McCracken, GH | 2 |
| Isani, Z | 1 |
| Rehman, N | 1 |
| Adil, N | 1 |
| el Messidi, M | 1 |
| Modai, J | 1 |
| Vittecoq, D | 1 |
| Decazes, JM | 1 |
| Wolff, M | 1 |
| Meulemans, A | 1 |
| Sakata, Y | 1 |
| Olsen, KD | 1 |
| Neu, HC | 1 |
| Greenman, RL | 1 |
| Arcey, SM | 1 |
| Dickinson, GM | 1 |
| Mokhbat, JE | 1 |
| Sabath, LD | 1 |
| Friedhoff, LT | 1 |
| Okura, K | 1 |
| Yamamoto, H | 1 |
| Kuroki, S | 1 |
2 reviews available for aztreonam and Meningitis
| Article | Year |
|---|---|
The use of aztreonam in pediatric patients: a review.
Topics: Adult; Aztreonam; Bacterial Infections; Gram-Negative Aerobic Bacteria; Humans; Infant, Newborn; Men | 1991 |
Aztreonam: review of the clinical experience and potential uses in pediatrics.
Topics: Adolescent; Aztreonam; Bacterial Infections; Child; Child, Preschool; Cross Reactions; Cystic Fibros | 1988 |
16 other studies available for aztreonam and Meningitis
| Article | Year |
|---|---|
Evaluation of aztreonam in experimental bacterial meningitis and cerebritis.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Encephalitis; Escherichia coli Infections; Female; Gentam | 1983 |
Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Chromatography, High Pressure Liquid; Female; Humans; Kinet | 1984 |
Aztreonam for treating meningitis caused by gram-negative rods.
Topics: Adult; Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gram-Negative Bacteria; Hum | 1991 |
Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Infant, Newborn; Infant, Premature, | 1989 |
Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.
Topics: Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gastroenteritis; Gram-Negative Bac | 1989 |
Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.
Topics: Abscess; Aerobiosis; Appendix; Aztreonam; Bacterial Infections; Cecal Diseases; Child, Preschool; Fe | 1989 |
Aztreonam in the treatment of bacterial meningitis.
Topics: Aztreonam; Bacterial Infections; Child, Preschool; Female; Humans; Infant; Male; Meningitis; Meningi | 1989 |
Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa.
Topics: Animals; Aztreonam; Brain; Cerebrospinal Fluid; Meningitis; Pseudomonas aeruginosa; Pseudomonas Infe | 1986 |
[Clinical evaluation of aztreonam against pediatric purulent meningitis].
Topics: Age Factors; Aztreonam; Child; Child, Preschool; Drug Evaluation; Escherichia coli; Female; Haemophi | 1988 |
Aztreonam in the treatment of gram-negative meningitis in children.
Topics: Anti-Bacterial Agents; Aztreonam; Child, Preschool; Escherichia coli Infections; Gram-Negative Bacte | 1987 |
Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis.
Topics: Adult; Aged; Aztreonam; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Parenteral; | 1986 |
Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Escherichia coli Infections; Male; Meningitis; Meningitis | 1985 |
Current state of infectious diseases--potential areas of directed therapy with aztreonam.
Topics: Abdomen; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Biliary Trac | 1985 |
Penetration of aztreonam into human cerebrospinal fluid in the presence of meningeal inflammation.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Female; Humans; Male; Meningitis; Meningitis, Meningo | 1985 |
[Clinical evaluation on aztreonam in pediatric field and fundamental study on its penetration into cerebrospinal fluid].
Topics: Adolescent; Age Factors; Aztreonam; Bacterial Infections; Child; Child, Preschool; Drug Evaluation; | 1985 |
[Penetration of aztreonam and ampicillin to cerebrospinal fluid in the concomitant administration to rabbits with Staphylococcus aureus meningitis].
Topics: Ampicillin; Animals; Aztreonam; Drug Combinations; Injections, Intravenous; Kinetics; Meningitis; Ra | 1985 |